RNA vaccines generate tumour specific immune responses with limited toxicity
Thomas Powles posted on X:
“Personalised cancer vaccine trials have started in the adjuvant setting in renal cancer KCRS (Kidney Cancer Research Summit) Toni Choueiri.
Phase II data show these RNA vaccines generate tumour specific immune responses with limited toxicity. Recruitment has stated at Barts in London.” .
Source: Thomas Powles/X
Professor Thomas Powles, specializing in urology cancer, holds the position of Professor at the University of London since 2012 and serves as the Director of Barts Cancer Centre, a CRUK Major Cancer Centre. With a role in biomarker development and drug strategies, he has secured multiple EMA and FDA approvals. His achievements include advancing front-line immune/targeted therapy combinations in RCC and immune checkpoint inhibition in bladder cancer.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023